Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEDALO
2023-506733-30-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by European Myeloma Network. Primary endpoint: MRD 10^-5 negativity rate in complete remission patients in first year. Planned start Feb 2024; status: authorised.
02
Drugs
daratumumabpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-506733-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506733-30-00.